BioVie Announces Amended Terms for Asset Acquisition from Privately Held NeurMedix
May 10, 2021, 3:20 pm
BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for chronic debilitating liver diseases, today announced amendments to certain terms for the previously announced acquisition of the biopharmaceutical assets of NeurMedix,
